Meta-analysis finds no significant association between statin use and sarcopenia in older adults

A systematic review and meta-analysis examined observational studies investigating the association between statin use and the development of sarcopenia in predominantly older adults aged 60 years and above from European and Asian populations. The analysis included a total of 9,080 participants. The comparator group was not consistently reported across the included studies.

The primary finding was no statistically significant association between statin exposure and sarcopenia, with a pooled odds ratio of 0.82 (95% confidence interval: 0.16 to 4.05). The direction of estimates from individual studies ranged from potentially harmful to mildly protective, but the overall meta-analysis did not reach statistical significance. Safety and tolerability data were not reported in the meta-analysis.

Key limitations severely restrict the interpretability of these findings. The analysis demonstrated extremely high statistical heterogeneity (I² = 99.6%), indicating substantial inconsistency in results across the included studies. There was also limited methodological consistency in how sarcopenia was defined and measured. The evidence is observational and cannot establish causation.

For clinical practice, this analysis does not provide clear evidence that statin use is associated with sarcopenia risk in older adults. However, the high heterogeneity and methodological inconsistencies mean the question remains unresolved. Clinicians should continue to monitor for muscle symptoms as part of routine statin management while recognizing the current evidence base is inconclusive regarding a specific link to sarcopenia.